What is the equivalent oral dose of N‑acetylcysteine for a patient receiving 1.2 g intravenously every 12 hours for contrast‑induced nephropathy prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oral NAC Dose Equivalent

The equivalent oral dose of N-acetylcysteine for a patient receiving 1.2 g IV every 12 hours is 600 mg orally twice daily (every 12 hours).

Evidence-Based Dosing

The guideline evidence consistently demonstrates that when NAC is used for contrast-induced nephropathy prophylaxis, the standard oral regimen is 600 mg twice daily 1, 2, 1. This dosing appears in multiple European Heart Journal guidelines (2009) and the European Society of Cardiology recommendations as a Class I, Level B recommendation 1.

The 2010 ESC guidelines on myocardial revascularization specifically state that NAC administration "may be considered" at 600-1200 mg 24 hours before and continued for 24 hours after the procedure 2. This provides a dosing range, but the lower end (600 mg twice daily) represents the standard dose.

Important Clinical Context

However, you should be aware that NAC is NOT recommended for CIN prophylaxis based on the highest quality evidence. The 2011 ACCF/AHA/SCAI guidelines explicitly state as a Class III recommendation (No Benefit) that "Administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced AKI" (Level of Evidence: A) 3.

This recommendation is based on:

  • The ACT (Acetylcysteine for Contrast-Induced Nephropathy Trial), the largest randomized study with 2,308 patients, which showed no benefit (12.7% CIN in both NAC and control groups) 4
  • An updated meta-analysis showing benefit only in low-quality studies with high risk of bias, but no effect in high-quality trials (RR 1.05; 95% CI 0.73-1.53) 4

Practical Algorithm

If you must continue NAC despite lack of efficacy:

  1. Standard oral dose: 600 mg PO twice daily
  2. High-dose oral regimen (if previously used): 1200 mg PO twice daily 2, 5, 6
  3. Duration: Start 24 hours before contrast exposure, continue for 24 hours after 2

What actually works for CIN prevention:

  • Isotonic saline hydration: 1 mL/kg/hr for 12 hours before and 24 hours after (or 1.0-1.5 mL/kg/hr for 3-12 hours before and 6-24 hours after) 1, 2, 3
  • Minimize contrast volume 3

Critical Pitfall

The most common error is continuing NAC based on older, lower-quality studies while neglecting adequate hydration. Hydration is the only proven intervention 3. The 2011 guidelines are clear that IV hydration is preferable to oral hydration, and isotonic saline is the standard of care 3.

If your institution protocol requires NAC continuation, the direct conversion from 1.2 g IV q12h would be 600 mg PO q12h, but strongly consider discontinuing NAC entirely and focusing on aggressive isotonic saline hydration instead.

Related Questions

What is the recommended N‑acetylcysteine (NAC) dosing regimen for preventing contrast‑induced nephropathy in adult patients?
What are the recommended adult dosing regimens of N‑acetylcysteine for mucolytic therapy, acute acetaminophen overdose, and prevention of contrast‑induced nephropathy?
What is the role of N-acetyl cysteine (NAC) in preventing contrast-associated nephropathy (CAN)?
What is the recommended dose of N-acetylcysteine (NAC) for a patient at risk of contrast-induced nephropathy?
What is the dose of acetylcysteine (N-acetylcysteine) for a short course in an adult with normal renal function?
What is the definition of poor R-wave progression on an electrocardiogram (ECG)?
What ketamine‑propofol (ketofol) bolus and infusion dosing regimen should be used for an average 70‑kg adult without severe cardiac or hepatic disease?
In a 59-year-old male with hypertension and chronic hepatitis B presenting with tense ascites, lower‑extremity edema, and dyspnea, what is the problem representation, major clinical syndromes, pathophysiology, differential diagnosis, most likely diagnosis, whether hemorrhagic ascites suggests hepatocellular carcinoma, evaluation for hepatorenal syndrome, Child‑Pugh class, MELD score, and the evidence‑based short‑ and long‑term management plan according to Harrison's Internal Medicine and AASLD cirrhosis guidelines?
A 45-year-old patient with hypotension, tachycardia, cool clammy skin, and a history of severe bleeding after a motor vehicle accident—what is the immediate first step in managing this hypovolemic shock?
Is a family history of asthma a risk factor for chronic obstructive pulmonary disease (COPD) in a patient without personal asthma?
In a 36-year-old woman with class III obesity, type 2 diabetes, moderate restrictive lung physiology, severe nocturnal hypoxemia, chronic hypercapnia, and an apnea‑hypopnea index of 6 events per hour, which complication is she at greatest risk for: pulmonary hypertension, stroke, or central sleep apnea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.